NEW YORK STATE COMMON RETIREMENT FUND - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 93 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2018. The put-call ratio across all filers is 0.14 and the average weighting 0.4%.

Quarter-by-quarter ownership
NEW YORK STATE COMMON RETIREMENT FUND ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q3 2023$164
-35.4%
18,994
-22.5%
0.00%
Q2 2023$254
-30.4%
24,506
-27.2%
0.00%
Q1 2023$365
-25.5%
33,671
-22.9%
0.00%
-100.0%
Q4 2022$490
-99.9%
43,654
-0.0%
0.00%0.0%
Q3 2022$443,000
+12.4%
43,659
+0.3%
0.00%0.0%
Q2 2022$394,000
+15.2%
43,518
+21.5%
0.00%
Q1 2022$342,000
-13.6%
35,817
+0.0%
0.00%
Q4 2021$396,000
+85.0%
35,806
+23.7%
0.00%
Q3 2021$214,000
-69.1%
28,951
-39.3%
0.00%
-100.0%
Q2 2021$693,000
-18.0%
47,694
+15.2%
0.00%0.0%
Q1 2021$845,000
+14.8%
41,4000.0%0.00%0.0%
Q4 2020$736,000
+20.3%
41,4000.0%0.00%0.0%
Q3 2020$612,000
-29.6%
41,4000.0%0.00%0.0%
Q2 2020$869,000
-10.9%
41,400
-1.9%
0.00%0.0%
Q1 2020$975,000
-10.8%
42,2000.0%0.00%0.0%
Q4 2019$1,093,000
+16.6%
42,200
-12.3%
0.00%0.0%
Q3 2019$937,000
+36.4%
48,100
+14.3%
0.00%0.0%
Q2 2019$687,000
-28.0%
42,1000.0%0.00%0.0%
Q1 2019$954,000
-11.4%
42,1000.0%0.00%
-50.0%
Q4 2018$1,077,000
-28.8%
42,100
-9.1%
0.00%0.0%
Q3 2018$1,513,000
+44.1%
46,3000.0%0.00%
+100.0%
Q2 2018$1,050,000
-6.5%
46,3000.0%0.00%0.0%
Q1 2018$1,123,000
-13.0%
46,3000.0%0.00%
-50.0%
Q4 2017$1,291,000
-18.5%
46,3000.0%0.00%0.0%
Q3 2017$1,585,000
-14.1%
46,3000.0%0.00%0.0%
Q2 2017$1,845,000
+18.2%
46,300
+9.2%
0.00%0.0%
Q1 2017$1,561,000
+28.2%
42,401
+11.0%
0.00%0.0%
Q4 2016$1,218,000
-12.0%
38,2000.0%0.00%0.0%
Q3 2016$1,384,000
+120.0%
38,200
+37.9%
0.00%
+100.0%
Q2 2016$629,000
+20.7%
27,7000.0%0.00%0.0%
Q1 2016$521,000
+36.4%
27,700
+18.9%
0.00%0.0%
Q4 2015$382,000
+49.2%
23,3000.0%0.00%
Q3 2015$256,000
-26.6%
23,300
-13.2%
0.00%
-100.0%
Q2 2015$349,00026,8300.00%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q1 2018
NameSharesValueWeighting ↓
Madison Avenue Partners, LP 7,269,584$69,497,223,00012.98%
Newtyn Management, LLC 1,375,000$13,145,0003.15%
Chescapmanager LLC 1,166,574$11,152,0001.51%
Baupost Group 13,643,333$130,430,0001.40%
Weiss Asset Management LP 5,412,487$51,743,0001.07%
CM Management, LLC 120,000$1,147,0000.96%
Orbimed Advisors 3,254,713$31,115,0000.50%
King Wealth Management Group 122,000$1,166,0000.23%
Woodline Partners LP 1,326,653$12,683,0000.21%
PDT Partners, LLC 192,701$1,842,0000.16%
View complete list of THERAVANCE BIOPHARMA INC shareholders